Ellen D Yorke1, Andrew Jackson2, Li Cheng Kuo2, Anthonia Ojo3, Kelly Panchoo3, Prasad Adusumilli4, Marjorie G Zauderer5, Valerie W Rusch4, Annemarie Shepherd3, Andreas Rimner3. 1. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: yorkee@mskcc.org. 2. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
PURPOSE: To determine clinically helpful dose-volume and clinical metrics correlating with symptomatic radiation pneumonitis (RP) in malignant pleural mesothelioma (MPM) patients with 2 lungs treated with hemithoracic intensity modulated pleural radiation therapy (IMPRINT). METHODS AND MATERIALS: Treatment plans and resulting normal organ dose-volume histograms of 103 consecutive MPM patients treated with IMPRINT (February 2005 to January 2015) to the highest dose ≤50.4 Gy satisfying departmental normal tissue constraints were uniformly recalculated. Patient records provided maximum RP grade (Common Terminology Criteria for Toxicity and Adverse Event version 4.0) and clinical and demographic information. Correlations analyzed with the Cox model were grade ≥2 RP (RP2+) and grade ≥3 RP (RP3+) with clinical variables, with volumes of planning target volume (PTV) and PTV-lung overlap and with mean dose, percent volume receiving dose D (VD), highest dose encompassing % volume V, (DV), and heart, total, ipsilateral, and contralateral lung volumes. RESULTS: Twenty-seven patients had RP2+ (14 with RP3+). The median prescription dose was 46.8 Gy (39.6-50.4 Gy, 1.8 Gy/fraction). The median age was 67.6 years (range, 42-83 years). There were 79 men, 40 never-smokers, and 44 with left-sided MPM. There were no significant (P≤.05) correlations with clinical variables, prescription dose, total lung dose-volume metrics, and PTV-lung overlap volume. Dose-volume correlations for heart were RP2+ with VD (35 ≤ D ≤ 47 Gy, V43 strongest at P=.003), RP3+ with VD (31 ≤ D ≤ 45 Gy), RP2+ with DV (5 ≤ V ≤ 30%), RP3+ with DV (15 ≤ V ≤ 35%), and mean dose. Significant for ipsilateral lung were RP2+ with VD (38 ≤ D ≤ 44 Gy), RP3+ with V41, RP2+ and RP3+ with minimum dose, and for contralateral lung, RP2+ with maximum dose. Correlation of PTV with RP2+ was strong (P<.001) and also significant with RP3+. CONCLUSIONS: Heart dose correlated strongly with symptomatic RP in this large cohort of MPM patients with 2 lungs treated with IMPRINT. Planning constraints to reduce future heart doses are suggested.
PURPOSE: To determine clinically helpful dose-volume and clinical metrics correlating with symptomatic radiation pneumonitis (RP) in malignant pleural mesothelioma (MPM) patients with 2 lungs treated with hemithoracic intensity modulated pleural radiation therapy (IMPRINT). METHODS AND MATERIALS: Treatment plans and resulting normal organ dose-volume histograms of 103 consecutive MPMpatients treated with IMPRINT (February 2005 to January 2015) to the highest dose ≤50.4 Gy satisfying departmental normal tissue constraints were uniformly recalculated. Patient records provided maximum RP grade (Common Terminology Criteria for Toxicity and Adverse Event version 4.0) and clinical and demographic information. Correlations analyzed with the Cox model were grade ≥2 RP (RP2+) and grade ≥3 RP (RP3+) with clinical variables, with volumes of planning target volume (PTV) and PTV-lung overlap and with mean dose, percent volume receiving dose D (VD), highest dose encompassing % volume V, (DV), and heart, total, ipsilateral, and contralateral lung volumes. RESULTS: Twenty-seven patients had RP2+ (14 with RP3+). The median prescription dose was 46.8 Gy (39.6-50.4 Gy, 1.8 Gy/fraction). The median age was 67.6 years (range, 42-83 years). There were 79 men, 40 never-smokers, and 44 with left-sided MPM. There were no significant (P≤.05) correlations with clinical variables, prescription dose, total lung dose-volume metrics, and PTV-lung overlap volume. Dose-volume correlations for heart were RP2+ with VD (35 ≤ D ≤ 47 Gy, V43 strongest at P=.003), RP3+ with VD (31 ≤ D ≤ 45 Gy), RP2+ with DV (5 ≤ V ≤ 30%), RP3+ with DV (15 ≤ V ≤ 35%), and mean dose. Significant for ipsilateral lung were RP2+ with VD (38 ≤ D ≤ 44 Gy), RP3+ with V41, RP2+ and RP3+ with minimum dose, and for contralateral lung, RP2+ with maximum dose. Correlation of PTV with RP2+ was strong (P<.001) and also significant with RP3+. CONCLUSIONS: Heart dose correlated strongly with symptomatic RP in this large cohort of MPMpatients with 2 lungs treated with IMPRINT. Planning constraints to reduce future heart doses are suggested.
Authors: Jerôme Krayenbuehl; Matthias Hartmann; Anthony J Lomax; Stephan Kloeck; Eugen B Hug; I Frank Ciernik Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-10 Impact factor: 7.038
Authors: Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Ellen X Huang; Andrew J Hope; Patricia E Lindsay; Marco Trovo; Issam El Naqa; Joseph O Deasy; Jeffrey D Bradley Journal: Acta Oncol Date: 2010-09-28 Impact factor: 4.089
Authors: Emilio Minatel; Marco Trovo; Jerry Polesel; Tania Baresic; Alessandra Bearz; Giovanni Franchin; Carlo Gobitti; Imad Abu Rumeileh; Annalisa Drigo; Paolo Fontana; Vittore Pagan; Mauro G Trovo Journal: Lung Cancer Date: 2013-10-27 Impact factor: 5.705
Authors: Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy Journal: Lancet Oncol Date: 2015-01-16 Impact factor: 41.316
Authors: Emilio Minatel; Marco Trovo; Jerry Polesel; Imad Abu Rumeileh; Tania Baresic; Alessandra Bearz; Alessandro Del Conte; Giovanni Franchin; Carlo Gobitti; Annalisa Drigo; Andrea Dassie; Vittore Pagan; Mauro G Trovo Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: David C Rice; W Roy Smythe; Zhongxing Liao; Thomas Guerrero; Joe Y Chang; Mary F McAleer; Melenda D Jeter; Arlene Correa; Ara A Vaporciyan; H Helen Liu; Ritsuko Komaki; Kenneth M Forster; Craig W Stevens Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-30 Impact factor: 7.038
Authors: Peter van Luijk; Hette Faber; Harm Meertens; Jacobus M Schippers; Johannes A Langendijk; Sytze Brandenburg; Harm H Kampinga; Robert P Coppes Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-01 Impact factor: 7.038
Authors: Guru Prasad Sharma; Brian L Fish; Anne C Frei; Jayashree Narayanan; Tracy Gasperetti; Dana Scholler; Lauren Pierce; Nathan Szalewski; Noah Blue; Meetha Medhora; Heather A Himburg Journal: Int J Radiat Oncol Biol Phys Date: 2022-01-29 Impact factor: 8.013
Authors: Annemarie F Shepherd; Michelle Iocolano; Jonathan Leeman; Brandon S Imber; Aaron T Wild; Michael Offin; Jamie E Chaft; James Huang; Andreas Rimner; Abraham J Wu; Daphna Y Gelblum; Narek Shaverdian; Charles B Simone; Daniel R Gomez; Ellen D Yorke; Andrew Jackson Journal: Pract Radiat Oncol Date: 2020-10-14